• 1
    Afari N, Buchwald D. Chronic fatigue syndrome: a review. Am J Psychiatry 2003; 160: 22136.
  • 2
    Plioplys S, Plioplys AV. Chronic fatigue syndrome (myalgic encephalopathy). South Med J 1995; 88: 9931000.
  • 3
    Plioplys S, Plioplys AV. Chronic fatigue syndrome (myalgic encephalopathy): a review. Chic Med 1995; 98: 115.
  • 4
    Royal Australasian College of Physicians Working Group. Chronic fatigue syndrome clinical practice guidelines – 2002. Med J Aust 2002; 176: S1756.
  • 5
    Reynolds KJ, Vernon SD, Bouchery E, Reeves WC. The economic impact of chronic fatigue syndrome. Cost Eff Resour Alloc 2004; 2: 4.
  • 6
    Jason LA, Benton MC, Valentine L, Johnson A, Torres-Harding S. The economic impact of ME/CFS: individual and societal costs. Dyn Med 2008; 7: 6.
  • 7
    Lloyd AR, Pender H. The economic impact of chronic fatigue syndrome. Med J Aust 1992; 157: 599601.
  • 8
    Anderson JS, Ferrans CE. The quality of life of persons with chronic fatigue syndrome. J Nerv Ment Dis 1997; 185: 35967.
  • 9
    Lombardi VC, Ruscetti FW, Das Gupta J et al. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2009; 326: 5859.
  • 10
    Erlwein O, Kaye S, McClure MO et al. Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome. PLoS ONE 2010; 5: e8519.
  • 11
    Groom HC, Boucherit VC, Makinson K et al. Absence of xenotropic murine leukaemia virus-related virus in UK patients with chronic fatigue syndrome. Retrovirology 2010; 7: 10.
  • 12
    Lo SC, Pripuzova N, Li B et al. Detection of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors. Proc Natl Acad Sci USA 2010; 107: 158749.
  • 13
    Switzer WM, Jia H, Hohn O et al. Absence of evidence of xenotropic murine leukemia virus-related virus infection in persons with chronic fatigue syndrome and healthy controls in the United States. Retrovirology 2010; 7: 57.
  • 14
    van Kuppeveld FJ, de Jong AS, Lanke KH et al. Prevalence of xenotropic murine leukaemia virus-related virus in patients with chronic fatigue syndrome in the Netherlands: retrospective analysis of samples from an established cohort. BMJ 2010; 340: c1018.
  • 15
    Bremer J. Carnitine – Metabolism and functions. Physiol Rev 1983; 63: 142080.
  • 16
    Engel AG, Angelini C. Carnitine deficiency of human skeletal muscle with associated lipid storage myopathy: a new syndrome. Science 1973; 179: 899902.
  • 17
    Bieber LL. Carnitine. Annu Rev Biochem 1988; 57: 26183.
  • 18
    Famularo G, Matricardi F, Nucera E, Santini G, De Simone C. Carnitine deficiency: Primary and secondary syndromes. In: De Simone C, Famularo G, eds Carnitine Today. Austin, USA: RG Landes Company, 1997; 11961.
  • 19
    Pons R, De Vivo DC. Primary and secondary carnitine deficiency syndromes. J Child Neurol 1995; 10(Suppl 2): S824.
  • 20
    Scholte HR, Rodrigues Pereira R, de Jonge PC, Luyt-Houwen IEM, Verduin MHM, Ross JD. Primary carnitine deficiency. J Clin Chem Clin Biochem 1990; 28: 3517.
  • 21
    Kuratsune H, Yamaguti K, Watanabe Y et al. Acylcarnitine and chronic fatigue syndrome. In: De Simone C, Famularo G, eds Carnitine Today. Austin, USA: RG Landes Company, 1997; 195213.
  • 22
    Kuratsune H, Yamaguti K, Lindh G et al. Low levels of serum acylcarnitine in chronic fatigue syndrome and chronic hepatitis type C, but not seen in other diseases. Int J Mol Med 1998; 2: 516.
  • 23
    Kuratsune H, Yamaguti K, Takahashi M, Misaki H, Tagawa S, Kitani T. Acylcarnitine deficiency in chronic fatigue syndrome. Clin Infect Dis 1994; 18(Suppl 1): S627.
  • 24
    Kuratsune H, Yamaguti K, Takahashi M, Tagawa S, Machii T, Kitani T. Abnormal cellular carnitine metabolism in chronic fatigue syndrome. EOS J Immunol Immunopharmacol 1995; 15: 404.
  • 25
    Li YJ, Wang DX, Bai XL et al. [Clinical characteristics of patients with chronic fatigue syndrome: analysis of 82 cases]. Zhonghua Yi Xue Za Zhi 2005; 85: 7014. (Abstract).
  • 26
    Plioplys AV, Plioplys S. Serum levels of carnitine in chronic fatigue syndrome: clinical correlates. Neuropsychobiology 1995; 32: 1328.
  • 27
    Jones MG, Goodwin CS, Amjad S, Chalmers RA. Plasma and urinary carnitine and acylcarnitines in chronic fatigue syndrome. Clin Chim Acta 2005; 360: 1737.
  • 28
    Majeed T, De Simone C, Famularo G, Marcellini S, Behan PO. Abnormalities of carnitine metabolism in chronic fatigue syndrome. Eur J Neurol 1995; 2: 4258.
  • 29
    Chace DH, Hillman SL, Van Hove JL, Naylor EW. Rapid diagnosis of MCAD deficiency: quantitative analysis of octanoylcarnitine and other acylcarnitines in newborn blood spots by tandem mass spectrometry. Clin Chem 1997; 43: 210613.
  • 30
    Chace DH, Kalas TA, Naylor EW. Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin Chem 2003; 49: 1797817.
  • 31
    Soetekouw PM, Wevers RA, Vreken P et al. Normal carnitine levels in patients with chronic fatigue syndrome. Neth J Med 2000; 57: 204.
  • 32
    Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 11213.
  • 33
    Taylor RR, Jason LA, Torres A. Fatigue rating scales: an empirical comparison. Psychol Med 2000; 30: 84956.
  • 34
    Edwards RH, Newham DJ, Peters TJ. Muscle biochemistry and pathophysiology in postviral fatigue syndrome. Br Med Bull 1991; 47: 82637.
  • 35
    Myhill S, Booth NE, McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med 2009; 2: 116.
  • 36
    Maes M, Mihaylova I, Leunis JC. In chronic fatigue syndrome, the decreased levels of omega-3 poly-unsaturated fatty acids are related to lowered serum zinc and defects in T cell activation. Neuro Endocrinol Lett 2005; 26: 74551.
  • 37
    Leonhardt M, Langhans W. Fatty acid oxidation and control of food intake. Physiol Behav 2004; 83: 64551.
  • 38
    Niot I, Gresti J, Boichot J et al. Effect of dietary n-3 and n-6 polyunsaturated fatty acids on lipid-metabolizing enzymes in obese rat liver. Lipids 1994; 29: 4819.
  • 39
    Vamecq J, Vallee L, de la Porte PL et al. Effect of various n-3/n-6 fatty acid ratio contents of high fat diets on rat liver and heart peroxisomal and mitochondrial beta-oxidation. Biochim Biophys Acta 1993; 1170: 1516.
  • 40
    Beermann C, Jelinek J, Reinecker T, Hauenschild A, Boehm G, Klor HU. Short term effects of dietary medium-chain fatty acids and n-3 long-chain polyunsaturated fatty acids on the fat metabolism of healthy volunteers. Lipids Health Dis 2003; 2(Art 1): 110.
  • 41
    Guebre-Egziabher F, Rabasa-Lhoret R, Bonnet F et al. Nutritional intervention to reduce the n-6/n-3 fatty acid ratio increases adiponectin concentration and fatty acid oxidation in healthy subjects. Eur J Clin Nutr 2008; 62: 128793.
  • 42
    Yoon HR, Hong YM, Boriack RL, Bennett MJ. Effect of L-carnitine supplementation on cardiac carnitine palmitoyltransferase activities and plasma carnitine concentrations in adriamycin-treated rats. Pediatr Res 2003; 53: 78892.
  • 43
    Plioplys AV, Plioplys S. Amantadine and L-carnitine treatment of chronic fatigue syndrome. Neuropsychobiology 1997; 35: 1623.
  • 44
    Vermeulen RCW, Scholte HR. Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome. Psychosom Med 2004; 66: 27682.
  • 45
    Puri BK. The use of eicosapentaenoic acid in the treatment of chronic fatigue syndrome. Prostaglandins Leukot Essent Fatty Acids 2004; 70: 399401.
  • 46
    Puri BK. Long-chain polyunsaturated fatty acids and the pathophysiology of myalgic encephalomyelitis (chronic fatigue syndrome). J Clin Pathol 2007; 60: 1224.
  • 47
    Tamizi farB, Tamizi B. Treatment of chronic fatigue syndrome by dietary supplementation with omega-3 fatty acids - A good idea? Med Hypotheses 2002; 58: 24950.
  • 48
    Piccoli C, Quarato G, Ripoli M et al. HCV infection induces mitochondrial bioenergetic unbalance: causes and effects. Biochim Biophys Acta 2009; 1787: 53946.